Summary
Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on January 9, 2009, to disclose information that will be presented at the J.P. Morgan 27th Annual Healthcare Conference. The filing primarily consists of slides prepared for investor meetings scheduled between January 12-15, 2009. Investors attending the conference or seeking an update on the company's progress should review these slides for the latest information. While the 8-K itself does not contain detailed financial statements or specific business updates beyond the announcement of presentation materials, the attached slides are intended to cover key aspects of Regeneron's business, pipeline, and strategic outlook. Investors are advised to access and analyze these slides to gain insights into the company's development programs and future prospects as presented to potential investors and analysts.
Key Highlights
- 1Regeneron Pharmaceuticals filed an 8-K on January 9, 2009.
- 2The filing's primary purpose is to disclose materials for the J.P. Morgan 27th Annual Healthcare Conference.
- 3Presentation slides intended for investor meetings are attached as Exhibit 99(a).
- 4The conference is scheduled to take place from January 12-15, 2009.
- 5The 8-K itself does not contain new financial data or operational details, but directs investors to the presentation materials for updates.
- 6Investors interested in Regeneron's current standing should seek out the slides referenced in the filing.